OTCPK:INNMF (Australia) Also Trade In: Australia
Amplia Therapeutics Ltd $ 0.09 0 (0%)
Warning! GuruFocus has detected 2 Severe warning signs with INNMF. Click here to check it out.
Avg Vol (1m):
Market Cap $:
Enterprise Value $:
Current and historical daily P/E ratio for Amplia Therapeutics Ltd () from 2015 to Sep 19 2020. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. Amplia Therapeutics stock (INNMF) PE ratio as of Sep 19 2020 is 0. More Details
Amplia Therapeutics PE Ratio (TTM) Historical Data
View and export this data going back to 2015. Start your Free Trial
Amplia Therapeutics PE Ratio (TTM) Comparison
|Company||Market Cap(Mil)||PE Ratio (TTM)|
Compare ASX:FIJ ASX:LCT ASX:BXN ASX:MEB ASX:ANR ASX:SUD ASX:NC6 ASX:AVE ASX:1AD ASX:IMC OCSE:NOVO B ASX:CSL NAS:VRTX NAS:REGN XKRX:207940 NAS:SGEN NAS:MRNA NAS:ALXN XKRX:068270 NAS:INCY
Address 55 Collins Street, Level 29, Melbourne, VIC, AUS, 3000
Amplia Therapeutics Ltd is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. Its molecule, AMP945 is a pure play inhibitor, while the second molecule, AMP886, is a multi-action molecule that hits two other important cancer pathways - VEGFR3 and FLT3.